Pipeline

One Pathway, Multiple Diseases

Our adenosine receptor antagonist platform spans oncology, neurology, and hematology, targeting diseases driven by adenosine pathway dysregulation.

Therapeutic Area
Indication
Asset
Target
Study
Discovery
Preclinical
Phase I/Ib
Phase II
ONCOLOGY
Mesothelioma★
TT-4
A2BR
Pleural Mesothelioma
Solid Tumors
TT-4 + TT-10
A2BR + A2AR
RCC, CRPC, NSCLC, HNSCC
Solid Tumors
TT-10
A2AR
RCC, CRPC, NSCLC, HNSCC
Gut-Cancers
TT-3
A2BR
-
IND Enabled
Solid Tumors
TT-53
A2AR/A2BR
-
Discovery
NEUROLOGY
Parkinson's Disease
TT-10
A2AR
-
Clinical Stage Asset
HEMATOLOGIC
Sickle Cell Disease
TT-4
A2BR
-
Clinical Stage Asset
★ Lead ProgramNCT = ClinicalTrials.gov registry identifier
50+
Granted Patents Across Global Jurisdictions
3
Clinical Assets
3
Therapeutic Areas
15+
World-Leading Experts

Featured Programs

Our Lead Programs

LEAD PROGRAM

TT-4 in Mesothelioma

A2BR Antagonist • Phase I/II

Our lead program targeting malignant pleural mesothelioma, a rare and aggressive cancer with limited treatment options. TT-4 is an investigational selective A2B receptor antagonist designed to block adenosine-mediated immunosuppression in the tumor microenvironment.

PHASE I/IB

TT-4 + TT-10 in Solid Tumors

Coordinated A2B/A2A Receptor Blockade • Phase I/IB

Our investigational add-on strategy evaluates TT-4, an A2B receptor antagonist, in combination with TT-10, an A2A receptor antagonist, in selected solid tumors where adenosine-driven immune suppression may contribute to treatment resistance.

This combination approach is designed to evaluate coordinated blockade of complementary adenosine receptor pathways in cancers with high unmet medical need, including renal cell carcinoma, head and neck cancer, prostate cancer, and non-small cell lung cancer.

Learn About Our Science

Understand the adenosine pathway and our differentiated therapeutic approach to A2B and A2A receptor blockade.

View ScienceMesothelioma Awareness